Current Approaches to the Use of Sirolimus In Renal Transplantation

Transplantation Proceedings

Volumn 41, Issue 8, 2009, Pages 3011-3015

  Kahan, B D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOTHELIUM CELL; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCELE; LYMPHOMA; NEPHROTOXICITY; POLYURIA; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SMOOTH MUSCLE FIBER; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

CALCINEURIN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TACROLIMUS;

EID: 70350514618     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.07.104     Document Type: Article

References (43)

1. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 (2003) 7S
2. Hong J.C., and Kahan B.D. Two paradigms for new immunosuppressive strategies in organ transplantation. Curr Opin Organ Transplant 3 (1998) 175
3. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 15;356 (2000) 194
4. MacDonald A.S., and RAPAMUNE Global Study Group A. Worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2001) 271
5. Gaber A.O., Kahan B.D., Van Buren C.T., et al., Sirolimus High Risk Study Group. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Transplantation 86 (2008) 1187
6. Reitamo S., Spuls P., Sassolas B., et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145 (2001) 438
7. Podder H., Stepkowski S.M., Napoli K., et al. Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction. J Am Soc Nephrol 12 (2001) 1059
8. Diekmann F., Budde K., Oppenheimer F., et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4 (2004) 1869
9. Rowshani A.T., Scholten E.M., Bemelman F., et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 17 (2006) 305
10. Marcen R., Pascual J., Terrel J.L., et al. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss?. Transplantation 72 (2001) 57
11. Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy. N Engl J Med 349 (2003) 2326
12. Hamdy A.F., El-Agroudy A.E., Bakr M.A., et al. Comparison of sirolimus with low-dose tacrolimus versus sirolimus. Am J Transplant 5 (2005) 2531
13. Groth C.G., Backman L., Morales J.M., et al. Sirolimus-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 67 (1999) 1036
14. Kreis H., Cisterne J.M., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69 (2000) 1252
15. Flechner S.M., Goldfarb D., Solez K., et al. Kidney transplantation with sirolimus and MMF-based immunosuppression: 5 year results of a randomized prospective trial compared to CNI drugs. Transplantation 83 (2007) 883
16. Büchler M., Caillard S., Barbier S., et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 7 (2007) 2522
17. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6 (2006) 514
18. Schaefer H.M., Kizilisik A.T., Feurer I., et al. Short-term results under three different immunosuppressive regimens at one center. Transplant Proc 38 (2006) 3466
19. Flechner S., Glyda M., Steinberg S., et al. A randomized, open label study to compare the safety and efficacy of two different sirolimus regimens with tacrolimus and mycophenolate mofetil regimen in de novo renal allograft recipient. Transplant Int 20 S2 (2007) 209
20. Johnson R.W., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777
21. Oberbauer R., Segoloni G., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18 (2005) 22
22. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
23. Weir M., Wali R., Pearson T.C., et al. Spare the Nephron Trial; Updated 1 year efficacy and safety of mycophenolate/sirolimus maintenance therapy after calcineurin inhibitor withdrawal. Am J Transplant 7 S2 (2007) 159
24. Lebranchu Y., Etienne I., Torichard G., et al. Comparison of efficacy and safety of cyclosporine discontinuation with introduction of sirolimus at weeks 12 to standard strategy in renal transplant recipients receiving mycophenolate mofetil (MMF). Am J Transplant 7 (2007) 160
25. Schena F.P., Vitko S., Wali R., et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus in renal allograft recipients: 13 month results from a randomized, open label comparison trial. Transplantation 82 (2006) 412
26. Vathsala A., Weinberg R.B., Schoenberg L., et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 48 (1989) 37
27. Hoogeveen R.C., Ballantyne C.M., Pownall H.J., et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 72 (2001) 1244
28. Morrisett J.D., Abdel-Fattah G., Hoogeveen R., et al. effects of sirolimus on plasma lipids, lipoprotein levels and fatty acid metabolism in renal transplant patients. J. Lipid Res 43 (2002) 1170
29. Chueh S.-C.J., and Kahan B.D. Dyslipidemia in renal transplant recipients treated with a sirolimus-cyclosporine based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 76 (2003) 375
30. Lisik W., Schoenberg L., Lasky R.E., et al. Statins benefit outcomes of renal transplant recipients on sirolimus-cyclosporine regimen. Transplant Proc 39 (2007) 3086
31. Knight R.J., Vathsala A., Schoenberg L., et al. Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. Transplantation 53 (1992) 224
32. Hong J.C., and Kahan B.D. Sirolimus-induced thrombocytopenia and leucopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69 (2000) 2085
33. Langer R.M., and Kahan B.D. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 74 (2002) 804
34. Kaplan M.J., Ellis C.N., Bata-Csorgo Z., et al. Systemic toxicity following administration of sirolimus for psoriasis: association of capilary leak syndrome. Arch Dermatol 135 (1999) 553
35. Lieberthal W., Furhro R., Andry C.C., et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol 281 (2001) F693
36. Briscoe D. mTOR inhibitors: understanding the clinical effects. Transplant Proc 40 Suppl (2008) S9
37. McTaggart R., Gottlieb D., Brooks J., et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3 (2003) 413
38. Knight R.J., and Kahan B.D. The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity?. Kidney Int 70 (2006) 994
39. Kahan B.D., Yakupoglu Y.K., Schoenberg, et al. Low incidence of malignancies among cyclosporine-sirolimus treated renal transplant recipients. Transplantation 80 (2005) 749
40. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883
41. Benavides C.A., Pollard V., Maniyyedi S., et al. BK virus associated nephrology in sirolimus-treated renal transplant patients. Transplantation 84 (2007) 83
42. Kahan B.D., Knight R., Schoenberg L., et al. Ten years of sirolimus therapy of human renal transplantation: the University of Texas of Houston experience. Transplant Proc 35 (2003) 25S
43. Champion L., Stern M., Israël-Biet D., et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144 (2006) 505